ERYTECH announces the procedures for making the preparatory documents available for the Combined General Meeting of June 24, 2022 – 05/24/2022 at 10:05 p.m.


ERYTECH announces the terms of provision


preparatory documents for


the Combined General Meeting of 2

4

June

2022


Lyon (France), and Cambridge, MA (US)

the

24

May 2

022



ERYTECH

Pharmaceuticals (Euronext

&

Nasdaq: ERYP), a clinical-stage biopharmaceutical company that develops innovative therapies by encapsulating drugs in red blood cells (RBCs),

announcement today

the procedures for making available the preparatory documents for the Combined General Meeting of June 24, 2022.

ERYTECH Pharma shareholders are invited to attend the Combined General Meeting to be held on June 24, 2022 at 9:00 a.m. at the InterContinental Paris – Le Grand hotel at 2 rue Scribe in Paris (75 009 – FRANCE).

Shareholders have the following options to participate in the General Meeting:

  1. Personally attend the General Assembly;

  2. Vote remotely by post or online on the secure voting platform

    Votaccess

    ; Where

  3. Give a power of attorney to any natural or legal person of their choice, under the applicable legal and regulatory conditions or give a proxy to the Chairman of the General Meeting. The latter will then issue on their behalf a vote in favor of the adoption of the draft resolutions presented or approved by the Board of Directors and a vote against the adoption of all the other projects.

Availability of documents relating to the General Meeting

The notice of meeting serving as a notice of meeting, including the agenda and the draft resolutions as well as the main procedures for participation and voting at the Combined General Meeting, has been published in the Bulletin des Annonces Légales et Obligatoires n° 59 of May 18, 20 22 .

The preparatory documents and information relating to this General Meeting are made available to shareholders under legal and regulatory conditions, and are available on the website: https://erytech.com, under “Investors / General Meeting / 2022”.

Shareholders are invited to regularly consult this section, which may be updated to specify the final terms of participation in this General Meeting according to health requirements and/or legal and regulatory requirements.

About ERYTECH and eryaspase

(GRASPA®)

www.erytech.com

Founded in Lyon in 2004, ERYTECH is a clinical-stage biopharmaceutical company that develops innovative therapies based on red blood cells to fight against cancers and orphan diseases. Leveraging its proprietary ERYCAPS® platform, an innovative technology for encapsulating drugs in red blood cells, ERYTECH is developing a portfolio of product candidates targeting markets with significant unmet medical needs. ERYTECH mainly focuses on the development of products targeting metabolic disturbances in cancer cells, in order to deprive them of the amino acids necessary for their growth and survival.

The Company’s lead product, eryaspase (GRASPA®), consisting of L-asparaginase encapsulated in red blood cells from donors, addresses the altered asparagine and glutamine metabolism of cancer cells. The proof of concept of eryaspase as a metabolic agent against cancer has been established in different trials on acute lymphoblastic leukemia (ALL) and pancreatic cancer. A phase 2 investigator-sponsored study (IST) evaluating the use of eryaspase in patients with ALL who developed hypersensitivity reactions to pegylated asparaginase recently showed positive results, based on which the Company intends to file for approval in the United States and potentially in other territories. A Phase 2 study in metastatic triple-negative breast cancer and an investigator-sponsored Phase 1 clinical study in the first-line treatment of advanced pancreatic cancer are ongoing.

Eryaspase has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity reactions to pegylated asparaginase and for the treatment of cancer of the advanced pancreas. The FDA and the European Medicines Agency have granted eryaspase orphan drug status for the treatment of ALL and pancreatic cancer. Eryaspase is not approved in any country.

ERYTECH produces its drug candidates for the treatment of patients in Europe at its GMP-compliant production site in Lyon, France, and believes it has the means to produce for patients in the United States thanks to its long-term supply agreement with Catalent, operating from ERYTECH’s former GMP production site in Princeton, New Jersey, USA.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (symbol: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135; symbol: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC

Mid

& Small, CAC All

Tradable

,

EnterNext

PEA-PME 150 and Next Biotech.

CONTACTS

ERYTECH

Eric Soyer

Chief Financial Officer and Director of Operations

NewCap

Mathilde Bohin/Louis-Victor Delouvrier

Investor Relations

Nicolas Merigeau

Media Relations

+33 (0)4 78 74 44 38

[email protected]

+33 (0)1 44 71 94 94

[email protected]

Enclosed

  • PR_ERYTECH_2022 General Assembly_vf



Source link -86